PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study
Our aim was to assess the role of positron emission computed tomography (PET/CT) with <sup>18</sup>F-choline (<sup>18</sup>F-FCH) or <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) in hepatocellular carcinoma (HCC) submitted to <sup>90<...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/11/2996 |
| _version_ | 1827644885623111680 |
|---|---|
| author | Luca Filippi Oreste Bagni Ermanno Notarianni Adelchi Saltarelli Cesare Ambrogi Orazio Schillaci |
| author_facet | Luca Filippi Oreste Bagni Ermanno Notarianni Adelchi Saltarelli Cesare Ambrogi Orazio Schillaci |
| author_sort | Luca Filippi |
| collection | DOAJ |
| description | Our aim was to assess the role of positron emission computed tomography (PET/CT) with <sup>18</sup>F-choline (<sup>18</sup>F-FCH) or <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) in hepatocellular carcinoma (HCC) submitted to <sup>90</sup>Y-radioembolization (<sup>90</sup>Y-TARE). We retrospectively analyzed clinical records of 21 HCC patients submitted to PET/CT with <sup>18</sup>F-fluorocholine (<sup>18</sup>F-FCH) or <sup>18</sup>F-fluodeoxyglucose (<sup>18</sup>F-FDG) before and 8 weeks after <sup>90</sup>Y-TARE. On pre-treatment PET/CT, 13 subjects (61.9%) were <sup>18</sup>F-FCH-positive, while 8 (38.1%) resulted <sup>18</sup>F-FCH-negative and <sup>18</sup>F-FDG-positive. At 8-weeks post <sup>90</sup>Y-TARE PET/CT, 13 subjects showed partial metabolic response and 8 resulted non-responders, with a higher response rate among <sup>18</sup>F-FCH-positive with respect to <sup>18</sup>F-FDG-positive patients (i.e., 76.9% vs. 37.5%, <i>p</i> = 0.46). Post-treatment PET/CT influenced patients’ clinical management in 10 cases (47.6%); in 8 subjects it provided indication for a second <sup>90</sup>Y-TARE targeting metabolically active HCC remnant, while in 2 patients it led to a PET-guided radiotherapy on metastatic nodes. By Kaplan–Meier analysis, patients’ age (≤69 y) and post <sup>90</sup>Y-TARE PET/CT’s impact on clinical management significantly correlated with overall survival (OS). In Cox multivariate analysis, PET/CT’s impact on clinical management remained the only predictor of patients’ OS (<i>p</i> < 0.001). In our real-world study, PET/CT with <sup>18</sup>F-FCH or <sup>18</sup>F-FDG influenced clinical management and affected the final outcome for HCC patients treated with <sup>90</sup>Y-TARE. |
| first_indexed | 2024-03-09T18:27:26Z |
| format | Article |
| id | doaj.art-76ac844bf4294e5fac298bf64ef05792 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T18:27:26Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-76ac844bf4294e5fac298bf64ef057922023-11-24T07:47:26ZengMDPI AGBiomedicines2227-90592022-11-011011299610.3390/biomedicines10112996PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World StudyLuca Filippi0Oreste Bagni1Ermanno Notarianni2Adelchi Saltarelli3Cesare Ambrogi4Orazio Schillaci5Nuclear Medicine Unit, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, ItalyNuclear Medicine Unit, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, ItalyDiagnostic and Interventional Unit, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, ItalyDiagnostic and Interventional Unit, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, ItalyDiagnostic and Interventional Unit, “Santa Maria Goretti” Hospital, Via Antonio Canova, 04100 Latina, ItalyDepartment of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133 Rome, ItalyOur aim was to assess the role of positron emission computed tomography (PET/CT) with <sup>18</sup>F-choline (<sup>18</sup>F-FCH) or <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) in hepatocellular carcinoma (HCC) submitted to <sup>90</sup>Y-radioembolization (<sup>90</sup>Y-TARE). We retrospectively analyzed clinical records of 21 HCC patients submitted to PET/CT with <sup>18</sup>F-fluorocholine (<sup>18</sup>F-FCH) or <sup>18</sup>F-fluodeoxyglucose (<sup>18</sup>F-FDG) before and 8 weeks after <sup>90</sup>Y-TARE. On pre-treatment PET/CT, 13 subjects (61.9%) were <sup>18</sup>F-FCH-positive, while 8 (38.1%) resulted <sup>18</sup>F-FCH-negative and <sup>18</sup>F-FDG-positive. At 8-weeks post <sup>90</sup>Y-TARE PET/CT, 13 subjects showed partial metabolic response and 8 resulted non-responders, with a higher response rate among <sup>18</sup>F-FCH-positive with respect to <sup>18</sup>F-FDG-positive patients (i.e., 76.9% vs. 37.5%, <i>p</i> = 0.46). Post-treatment PET/CT influenced patients’ clinical management in 10 cases (47.6%); in 8 subjects it provided indication for a second <sup>90</sup>Y-TARE targeting metabolically active HCC remnant, while in 2 patients it led to a PET-guided radiotherapy on metastatic nodes. By Kaplan–Meier analysis, patients’ age (≤69 y) and post <sup>90</sup>Y-TARE PET/CT’s impact on clinical management significantly correlated with overall survival (OS). In Cox multivariate analysis, PET/CT’s impact on clinical management remained the only predictor of patients’ OS (<i>p</i> < 0.001). In our real-world study, PET/CT with <sup>18</sup>F-FCH or <sup>18</sup>F-FDG influenced clinical management and affected the final outcome for HCC patients treated with <sup>90</sup>Y-TARE.https://www.mdpi.com/2227-9059/10/11/2996positron emission tomographymolecular imaginghepatocellular carcinoma<sup>90</sup>Y-microspheres<sup>18</sup>F-choline<sup>18</sup>F-FDG |
| spellingShingle | Luca Filippi Oreste Bagni Ermanno Notarianni Adelchi Saltarelli Cesare Ambrogi Orazio Schillaci PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study Biomedicines positron emission tomography molecular imaging hepatocellular carcinoma <sup>90</sup>Y-microspheres <sup>18</sup>F-choline <sup>18</sup>F-FDG |
| title | PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study |
| title_full | PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study |
| title_fullStr | PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study |
| title_full_unstemmed | PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study |
| title_short | PET/CT with <sup>18</sup>F-choline or <sup>18</sup>F-FDG in Hepatocellular Carcinoma Submitted to <sup>90</sup>Y-TARE: A Real-World Study |
| title_sort | pet ct with sup 18 sup f choline or sup 18 sup f fdg in hepatocellular carcinoma submitted to sup 90 sup y tare a real world study |
| topic | positron emission tomography molecular imaging hepatocellular carcinoma <sup>90</sup>Y-microspheres <sup>18</sup>F-choline <sup>18</sup>F-FDG |
| url | https://www.mdpi.com/2227-9059/10/11/2996 |
| work_keys_str_mv | AT lucafilippi petctwithsup18supfcholineorsup18supffdginhepatocellularcarcinomasubmittedtosup90supytarearealworldstudy AT orestebagni petctwithsup18supfcholineorsup18supffdginhepatocellularcarcinomasubmittedtosup90supytarearealworldstudy AT ermannonotarianni petctwithsup18supfcholineorsup18supffdginhepatocellularcarcinomasubmittedtosup90supytarearealworldstudy AT adelchisaltarelli petctwithsup18supfcholineorsup18supffdginhepatocellularcarcinomasubmittedtosup90supytarearealworldstudy AT cesareambrogi petctwithsup18supfcholineorsup18supffdginhepatocellularcarcinomasubmittedtosup90supytarearealworldstudy AT orazioschillaci petctwithsup18supfcholineorsup18supffdginhepatocellularcarcinomasubmittedtosup90supytarearealworldstudy |